WESTLAKE VILLAGE, CA
Zoryve cream cleared for pediatric plaque psoriasis
- Sponsor
- Arcutis Biotherapeutics $ARQT
- Drug
- Zoryve · roflumilast
- Indication
- Plaque psoriasis in patients aged 2 and older (topical, cream 0.3%)
FDA approved Arcutis's Zoryve (roflumilast) cream 0.3% for the topical treatment of plaque psoriasis in children aged 2 and older, expanding the label from its prior adult and adolescent indications.
Read original at drugs.com ↗Drug Watch — recent news on Zoryve
- FDA Approves Zoryve Foam for Seborrheic Dermatitis - Managed Healthcare Executive
- Arcutis at Morgan Stanley conference: zoryve drives growth push - Investing.com
- ARQT: Strong ZORYVE sales, pipeline expansion, and AI-driven initiatives fuel sustained growth - TradingView
- ARQT: ZORYVE's growth, pipeline expansion, and digital initiatives drive robust outlook and cash flow - TradingView
- Azithromycin or Roflumilast to Prevent COPD Exacerbations? - NEJM Clinician
Sponsor Watch — recent news on Arcutis Biotherapeutics
- Can AstraZeneca's Broad Pipeline Offset Recent Setbacks?
- AstraZeneca (LSE:AZN) Reported First HER2 Directed Lung Cancer Phase III Success
- AstraZeneca (AZN)’s Lung Drug Delivers the Good News its Pipeline Needed
- FDA Grants Priority Review to AZN's Filing for Rare Bone Disease Drug
- Onco360® Has Been Selected as a National Pharmacy Partner for ETCAMAH™ (camizestrant)